Current Therapeutic Strategies and Novel Approaches in Osteosarcoma

Meyers, 1997, Osteosarcoma, Pediatr. Clin. North Am., 44, 973, 10.1016/S0031-3955(05)70540-X

Dorfman, 1995, Bone cancers, Cancer, 75, 203, 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V

Stiller, 2007, International patterns of cancer incidence in adolescents, Cancer Treat. Rev., 33, 631, 10.1016/j.ctrv.2007.01.001

Coventry, 1957, Osteogenic sarcoma—A critical analysis of 430 cases, J. Bone Joint Surg. Am., 39, 741, 10.2106/00004623-195739040-00002

Marcove, 1970, Osteogenic sarcoma under the age of twenty-one—A review of one hundred and forty-five operative cases, J. Bone Joint Surg. Am., 52, 411, 10.2106/00004623-197052030-00001

Bacci, 2000, Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report, J. Clin. Oncol., 18, 4016, 10.1200/JCO.2000.18.24.4016

Kager, 2003, Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols, J. Clin. Oncol., 21, 2011, 10.1200/JCO.2003.08.132

Bielack, 1999, Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the cooperative osteosarcoma study group coss of 925 patients, Klin. Padiatr., 211, 260, 10.1055/s-2008-1043798

Allison, 2012, A meta-analysis of osteosarcoma outcomes in the modern medical era, Sarcoma, 2012, 704872, 10.1155/2012/704872

Heymann, 2011, Bone sarcomas: Pathogenesis and new therapeutic approaches, IBMS BoneKEy, 8, 402, 10.1138/20110531

Jaffe, 2002, Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?, Cancer, 95, 2202, 10.1002/cncr.10944

Marina, 2004, Biology and therapeutic advances for pediatric osteosarcoma, Oncologist, 9, 422, 10.1634/theoncologist.9-4-422

Bacci, 2007, Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41–60 years: Outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999, Acta Orthop., 78, 377, 10.1080/17453670710013960

Rosen, 1982, Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy, Cancer, 49, 1221, 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E

Bruland, 2005, Hematogenous micrometastases in osteosarcoma patients, Clin. Cancer Res., 11, 4666, 10.1158/1078-0432.CCR-05-0165

Marulanda, 2008, Orthopedic surgery options for the treatment of primary osteosarcoma, Cancer Control, 15, 13, 10.1177/107327480801500103

Enneking, 1980, A system for the surgical staging of musculoskeletal sarcoma, Clin. Orthop. Relat. Res., 153, 106, 10.1097/00003086-198011000-00013

Patel, 2002, Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults, Am. J. Clin. Oncol., 25, 489, 10.1097/00000421-200210000-00014

Friedman, 1972, The therapy of osteogenic sarcoma: Current status and thoughts for the future, J. Surg. Oncol., 4, 482, 10.1002/jso.2930040512

Grimer, 2005, Surgical options for children with osteosarcoma, Lancet Oncol., 6, 85, 10.1016/S1470-2045(05)01734-1

Simon, 1986, Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur, J. Bone Joint Surg. Am., 68, 1331, 10.2106/00004623-198668090-00005

Rougraff, 1994, Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study, J. Bone Joint Surg. Am., 76, 649, 10.2106/00004623-199405000-00004

Grimer, 2002, Surgical outcomes in osteosarcoma, J. Bone Joint Surg. Br., 84, 395, 10.1302/0301-620X.84B3.0840395

Nagarajan, 2002, Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: What are the long-term implications?, J. Clin. Oncol., 20, 4493, 10.1200/JCO.2002.09.006

Smith, 1995, Phantom limb pain and chemotherapy in pediatric amputees, Mayo Clin. Proc., 70, 357, 10.4065/70.4.357

Krane, 1995, The prevalence of phantom sensation and pain in pediatric amputees, J. Pain Symptom Manage., 10, 21, 10.1016/0885-3924(94)00062-P

Bielack, 2002, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols, J. Clin. Oncol., 20, 776, 10.1200/JCO.2002.20.3.776

Arndt, 2012, Common musculoskeletal tumors of childhood and adolescence, Mayo Clin. Proc., 87, 475, 10.1016/j.mayocp.2012.01.015

Bielack, 2009, Osteosarcoma: The coss experience, Cancer Treat. Res., 152, 289, 10.1007/978-1-4419-0284-9_15

Gosheger, 2006, Endoprosthetic reconstruction in 250 patients with sarcoma, Clin. Orthop. Relat. Res., 450, 164, 10.1097/01.blo.0000223978.36831.39

Wittig, 2002, Osteosarcoma: A multidisciplinary approach to diagnosis and treatment, Am. Fam. Physician, 65, 1123

Ferrari, 2005, Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the italian and scandinavian sarcoma groups, J. Clin. Oncol., 23, 8845, 10.1200/JCO.2004.00.5785

Gherlinzoni, 1992, Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto rizzoli experience, Ann. Oncol., 3, S23, 10.1093/annonc/3.suppl_2.S23

Ceelen, 2007, Surgical trauma, minimal residual disease and locoregional cancer recurrence, Cancer Treat. Res., 134, 51

Kotz, 2000, A self-extending paediatric leg implant, Nature, 406, 143, 10.1038/35018155

Maronna, 1993, The blauth total knee endoprosthesis. Eighteen years’ experience in practice, Int. Orthop., 17, 17

Wunder, 2001, Comparison of two methods of reconstruction for primary malignant tumors at the knee: A sequential cohort study, J. Surg. Oncol., 77, 89, 10.1002/jso.1076

Jeys, 2005, Periprosthetic infection in patients treated for an orthopaedic oncological condition, J. Bone Joint Surg. Am., 87, 842, 10.2106/00004623-200504000-00021

Gaur, 2005, Infections in children and young adults with bone malignancies undergoing limb-sparing surgery, Cancer, 104, 602, 10.1002/cncr.21212

Grimer, 2002, Two-stage revision for infected endoprostheses used in tumor surgery, Clin. Orthop. Relat. Res., 395, 193, 10.1097/00003086-200202000-00022

Ceruso, 2001, Skeletal reconstruction with a free vascularized fibula graft associated to bone allograft after resection of malignant bone tumor of limbs, Handchir. Mikrochir. Plast. Chir., 33, 277, 10.1055/s-2001-16597

Manfrini, 2003, The role of vascularized fibula in skeletal reconstruction, Chir. Organi Mov., 88, 137

Uyttendaele, 1988, Limb conservation in primary bone tumours by resection, extracorporeal irradiation and re-implantation, J. Bone Joint Surg. Br., 70, 348, 10.1302/0301-620X.70B3.3163694

Morello, 2003, Pasteurized tumoral autograft and adjuvant chemotherapy for the treatment of canine distal radial osteosarcoma: 13 cases, Vet. Surg., 32, 539, 10.1111/j.1532-950X.2003.00539.x

Mankin, 1996, Long-term results of allograft replacement in the management of bone tumors, Clin. Orthop. Relat. Res., 324, 86, 10.1097/00003086-199603000-00011

Gebhardt, 1997, The results of transplantation of intercalary allografts after resection of tumors. A long-term follow-up study, J. Bone Joint Surg. Am., 79, 97, 10.2106/00004623-199701000-00010

Berrey, 1990, Fractures of allografts. Frequency, treatment, and end-results, J. Bone Joint Surg. Am., 72, 825, 10.2106/00004623-199072060-00005

Hornicek, 2001, Factors affecting nonunion of the allograft-host junction, Clin. Orthop. Relat. Res., 1, 87, 10.1097/00003086-200101000-00014

Mankin, 1992, Current status of allografting for bone tumors, Orthopedics, 15, 1147, 10.3928/0147-7447-19921001-05

Kotz, 1982, Rotation-plasty for childhood osteosarcoma of the distal part of the femur, J. Bone Joint Surg. Am., 64, 959, 10.2106/00004623-198264070-00001

Zeltzer, 1980, Psychologic effects of illness in adolescence. II. Impact of illness in adolescents—Crucial issues and coping styles, J. Pediatr., 97, 132, 10.1016/S0022-3476(80)80153-3

Picci, 1997, Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities, Ann. Oncol., 8, 899, 10.1023/A:1008230801849

Bacci, 2005, Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at rizzoli institute, Italy, Eur. J. Cancer, 41, 2836, 10.1016/j.ejca.2005.08.026

Meyers, 1993, Osteogenic sarcoma with clinically detectable metastasis at initial presentation, J. Clin. Oncol., 11, 449, 10.1200/JCO.1993.11.3.449

Harris, 1998, Treatment of metastatic osteosarcoma at diagnosis: A pediatric oncology group study, J. Clin. Oncol., 16, 3641, 10.1200/JCO.1998.16.11.3641

Goorin, 2002, Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial, J. Clin. Oncol., 20, 426, 10.1200/JCO.2002.20.2.426

Ferguson, 2001, Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric oncology group trial, J. Pediatr. Hematol. Oncol., 23, 340, 10.1097/00043426-200108000-00004

Bacci, 1997, Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions, Cancer, 79, 245, 10.1002/(SICI)1097-0142(19970115)79:2<245::AID-CNCR7>3.0.CO;2-J

Briccoli, 2005, Resection of recurrent pulmonary metastases in patients with osteosarcoma, Cancer, 104, 1721, 10.1002/cncr.21369

Marcove, 1973, Prolonged survival in osteogenic sarcoma with multiple pulmonary metastases. A case report and review of the literature, J. Bone Joint Surg. Am., 55, 1516, 10.2106/00004623-197355070-00020

Harting, 2006, Management of osteosarcoma pulmonary metastases, Semin. Pediatr. Surg., 15, 25, 10.1053/j.sempedsurg.2005.11.005

Ward, 1994, Pulmonary metastases of stage iib extremity osteosarcoma and subsequent pulmonary metastases, J. Clin. Oncol., 12, 1849, 10.1200/JCO.1994.12.9.1849

Glasser, 1992, Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience, Cancer, 69, 698, 10.1002/1097-0142(19920201)69:3<698::AID-CNCR2820690317>3.0.CO;2-G

Picci, 1985, Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor, Cancer, 56, 1515, 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6

Bielack, 2009, Osteosarcoma: Esmo clinical recommendations for diagnosis, treatment and follow-up, Ann. Oncol., 20, iv137, 10.1093/annonc/mdp154

Chou, 2006, Chemotherapy resistance in osteosarcoma: Current challenges and future directions, Expert Rev. Anticancer Ther., 6, 1075, 10.1586/14737140.6.7.1075

Campanacci, 1981, The treatment of osteosarcoma of the extremities: Twenty year’s experience at the istituto ortopedico rizzoli, Cancer, 48, 1569, 10.1002/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO;2-X

Enneking, 1979, Advances and treatment of primary bone tumors, J. Fla. Med. Assoc., 66, 28

Rosenburg, 1979, Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation, Cancer Treat. Rep., 63, 739

Rosen, 1976, Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, 37, 1, 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3

Voute, 1989, Experience with ifosfamide in paediatric tumours, Cancer Chemother. Pharmacol., 24, S28, 10.1007/BF00253235

Bacci, 2002, High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an italian sarcoma group/scandinavian sarcoma group pilot study, J. Chemother., 14, 198, 10.1179/joc.2002.14.2.198

Anninga, 2011, Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?, Eur. J. Cancer, 47, 2431, 10.1016/j.ejca.2011.05.030

Meyers, 1992, Chemotherapy for nonmetastatic osteogenic sarcoma: The memorial sloan-kettering experience, J. Clin. Oncol., 10, 5, 10.1200/JCO.1992.10.1.5

Avella, 1988, Adjuvant chemotherapy with six drugs (adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form, Chemioterapia, 7, 133

Rollins, 2005, Pemetrexed: A multitargeted antifolate, Clin. Ther., 27, 1343, 10.1016/j.clinthera.2005.09.010

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J. Clin. Oncol., 21, 2636, 10.1200/JCO.2003.11.136

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J. Clin. Oncol., 26, 3543, 10.1200/JCO.2007.15.0375

Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5

Bodmer, 2008, Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines, Pediatr. Blood Cancer, 50, 905, 10.1002/pbc.21236

Duffaud, 2012, A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma, Eur. J. Cancer, 48, 564, 10.1016/j.ejca.2011.12.015

Warwick, 2012, Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A children's oncology group study, Pediatr. Blood Cancer, 60, 237, 10.1002/pbc.24244

Meyers, 2008, Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the children's oncology group, J. Clin. Oncol., 26, 633, 10.1200/JCO.2008.14.0095

Ando, 2011, Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opin. Pharmacother., 12, 285, 10.1517/14656566.2011.543129

Hudson, 1990, Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience, J. Clin. Oncol., 8, 1988, 10.1200/JCO.1990.8.12.1988

Rosen, 1994, The role of thoracic surgery in the management of metastatic osteogenic sarcoma, Chest Surg. Clin. N. Am., 4, 75

Mori, 2008, Liposomal muramyl tripeptide phosphatidyl ethanolamine: A safe and effective agent against osteosarcoma pulmonary metastases, Expert Rev. Anticancer Ther., 8, 151, 10.1586/14737140.8.2.151

Machak, 2003, Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities, Mayo Clin. Proc., 78, 147, 10.4065/78.2.147

Delaney, 2005, The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines, Cancer, 104, 1129, 10.1002/cncr.21324

Schwarz, 2009, The role of radiotherapy in oseosarcoma, Cancer Treat. Res., 152, 147, 10.1007/978-1-4419-0284-9_7

DeLaney, 2005, Radiotherapy for local control of osteosarcoma, Int. J. Radiat. Oncol. Biol. Phys., 61, 492, 10.1016/j.ijrobp.2004.05.051

Ozaki, 2003, Osteosarcoma of the pelvis: Experience of the cooperative osteosarcoma study group, J. Clin. Oncol., 21, 334, 10.1200/JCO.2003.01.142

Ozaki, 2002, Osteosarcoma of the spine: Experience of the cooperative osteosarcoma study group, Cancer, 94, 1069, 10.1002/cncr.10258

Lee, 1971, Treatment of bone sarcoma, Proc. R. Soc. Med., 64, 1179

Phillips, 1969, Radiatio herapy of malignant bone tumors, Radiology, 92, 1537, 10.1148/92.7.1537

Ciernik, 2011, Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma, Cancer, 117, 4522, 10.1002/cncr.26037

Matsunobu, 2012, Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk, Cancer, 118, 4555, 10.1002/cncr.27451

Blakely, 1998, Heavy-ion radiobiology: New approaches to delineate mechanisms underlying enhanced biological effectiveness, Radiat. Res., 150, 126, 10.2307/3579815

Kamada, 2002, Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas, J. Clin. Oncol., 20, 4466, 10.1200/JCO.2002.10.050

Spira, 1968, Extracorporeal irradiation of bone tumors. A preliminary report, Isr. J. Med. Sci., 4, 1015

Araki, 1999, Intraoperative extracorporeal autogenous irradiated bone grafts in tumor surgery, Clin. Orthop. Relat. Res., 368, 196, 10.1097/00003086-199911000-00024

Hong, 2001, Extracorporeal irradiation for malignant bone tumors, Int. J. Radiat. Oncol. Biol. Phys., 50, 441, 10.1016/S0360-3016(01)01460-2

Yamamoto, 2002, Osteosarcoma of the distal radius treated by intraoperative extracorporeal irradiation, J. Hand Surg. Am., 27, 160, 10.1053/jhsu.2002.29482

Weichselbaum, 1977, Preliminary results of aggressive multimodality therapy for metastatic osteosarcoma, Cancer, 40, 78, 10.1002/1097-0142(197707)40:1<78::AID-CNCR2820400115>3.0.CO;2-5

Giritsky, 1978, Pulmonary resection in children with metastatic osteogenic sarcoma: Improved survival with surgery, chemotherapy, and irradiation, J. Thorac. Cardiovasc. Surg., 75, 354, 10.1016/S0022-5223(19)41261-0

Rab, 1976, Elective whole lung irradiation in the treatment of osteogenic sarcoma, Cancer, 38, 939, 10.1002/1097-0142(197608)38:2<939::AID-CNCR2820380243>3.0.CO;2-Y

Breur, 1978, Irradiation of the lungs as an adjuvant therapy in the treatment of osteosarcoma of the limbs. An EORTC randomized study, Eur. J. Cancer, 14, 461, 10.1016/0014-2964(78)90247-5

Gilchrist, 1981, Management of osteogenic sarcoma: A perspective based on the mayo clinic experience, Natl. Cancer Inst. Monogr., 56, 193

Whelan, 2002, A systematic review of the role of pulmonary irradiation in the management of primary bone tumours, Ann. Oncol., 13, 23, 10.1093/annonc/mdf047

(1988). Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer, 61, 1304–1311.

Anderson, 2002, High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases, J. Clin. Oncol., 20, 189, 10.1200/JCO.2002.20.1.189

Bruland, 1996, Targeted radiotherapy of osteosarcoma using 153 sm-edtmp. A new promising approach, Acta Oncol., 35, 381, 10.3109/02841869609101655

Anderson, 2007, Samarium lexidronam (153sm-edtmp): Skeletal radiation for osteoblastic bone metastases and osteosarcoma, Expert Rev. Anticancer Ther., 7, 1517, 10.1586/14737140.7.11.1517

Franzius, 2001, High.-activity samarium-153-edtmp therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma, Nuklearmedizin, 40, 215, 10.1055/s-0038-1625284

Whelan, 2010, The role of interferons in the treatment of osteosarcoma, Pediatr. Blood Cancer, 54, 350, 10.1002/pbc.22136

Einhorn, 1977, Is interferon tissue specific?—Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines, J. Gen. Virol., 35, 573, 10.1099/0022-1317-35-3-573

Strander, 1977, Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture, Int. J. Cancer, 19, 468, 10.1002/ijc.2910190406

Brosjo, 1987, Growth inhibition of human osteosarcomas in nude mice by human interferon-alpha: Significance of dose and tumor differentiation, Cancer Res., 47, 258

Mori, 2006, Osteosarcoma: Current status of immunotherapy and future trends (review), Oncol. Rep., 15, 693

Muller, 2005, Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the karolinska hospital series, Acta Oncol., 44, 475, 10.1080/02841860510029978

Strander, 1995, Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study, Acta Oncol., 34, 877, 10.3109/02841869509127199

Winkler, 1984, Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative german/austrian study, J. Clin. Oncol., 2, 617, 10.1200/JCO.1984.2.6.617

Anderson, 1999, Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases, Clin. Cancer Res., 5, 2316

Arndt, 2010, Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the children's oncology group, Clin. Cancer Res., 16, 4024, 10.1158/1078-0432.CCR-10-0662

Yeatman, 2004, A renaissance for src, Nat. Rev. Cancer, 4, 470, 10.1038/nrc1366

Shor, 2007, Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on src kinase for survival, Cancer Res., 67, 2800, 10.1158/0008-5472.CAN-06-3469

Manetti, 2007, Identification of a novel pyrazolo [3,4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice, J. Med. Chem., 50, 5579, 10.1021/jm061449r

Hingorani, 2009, Inhibition of src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo, Clin. Cancer Res., 15, 3416, 10.1158/1078-0432.CCR-08-1657

Nuzzi, 1999, The fkbp12-rapamycin-binding domain is required for fkbp12-rapamycin-associated protein kinase activity and g1 progression, J. Biol. Chem., 274, 4266, 10.1074/jbc.274.7.4266

Ory, 2007, Mtor inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: Bi-functional compounds for the treatment of bone tumours, Curr. Med. Chem., 14, 1381, 10.2174/092986707780831159

Wan, 2005, Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma, Cancer Res., 65, 2406, 10.1158/0008-5472.CAN-04-3135

Houghton, 2008, Initial testing (stage 1) of the mtor inhibitor rapamycin by the pediatric preclinical testing program, Pediatr. Blood Cancer, 50, 799, 10.1002/pbc.21296

Chawla, 2012, Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas, J. Clin. Oncol., 30, 78, 10.1200/JCO.2011.35.6329

McMahon, 2003, 1 Developmental roles and clinical significance of hedgehog signaling, Curr. Top. Dev. Biol., 53, 1, 10.1016/S0070-2153(03)53002-2

Lum, 2004, The hedgehog response network: Sensors, switches, and routers, Science, 304, 1755, 10.1126/science.1098020

Rubin, 2006, Targeting the hedgehog pathway in cancer, Nat. Rev. Drug Discov., 5, 1026, 10.1038/nrd2086

Lin, 2012, Hedgehog pathway as a drug target: Smoothened inhibitors in development, Oncotargets Ther., 5, 47, 10.2147/OTT.S21957

Xu, 2009, Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer, Cancer Lett., 283, 119, 10.1016/j.canlet.2009.01.014

Rudin, 2009, Treatment of medulloblastoma with hedgehog pathway inhibitor gdc-0449, N. Engl. J. Med., 361, 1173, 10.1056/NEJMoa0902903

LoRusso, 2009, Inhibition of the hedgehog pathway in advanced basal-cell carcinoma, N. Engl. J. Med., 361, 1164, 10.1056/NEJMoa0905360

Tang, 2012, Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome, N. Engl. J. Med., 366, 2180, 10.1056/NEJMoa1113538

Paget, 2012, Studying the role of the immune system on the antitumor activity of a hedgehog inhibitor against murine osteosarcoma, Oncoimmunology, 1, 1313, 10.4161/onci.21680

Hassan, 2012, Cell surface receptor expression patterns in osteosarcoma, Cancer, 118, 740, 10.1002/cncr.26339

Abdeen, 2009, Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma, Cancer, 115, 5243, 10.1002/cncr.24562

Wang, 2012, Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma, J. Surg. Oncol., 105, 235, 10.1002/jso.22077

Bagatell, 2011, Pharmacokinetically guided phase 1 trial of the igf-1 receptor antagonist rg1507 in children with recurrent or refractory solid tumors, Clin. Cancer Res., 17, 611, 10.1158/1078-0432.CCR-10-1731

Kolb, 2010, R1507, a fully human monoclonal antibody targeting igf-1r, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts, Pediatr. Blood Cancer, 55, 67, 10.1002/pbc.22479

Kolb, 2008, Initial testing of dasatinib by the pediatric preclinical testing program, Pediatr. Blood Cancer, 50, 1198, 10.1002/pbc.21368

Gorlick, 1999, Expression of her2/erbb-2 correlates with survival in osteosarcoma, J. Clin. Oncol., 17, 2781, 10.1200/JCO.1999.17.9.2781

Kilpatrick, 2001, Clinicopathologic analysis of her-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma, Mod. Pathol., 14, 1277, 10.1038/modpathol.3880474

Ebb, 2012, Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children’s oncology group, J. Clin. Oncol., 30, 2545, 10.1200/JCO.2011.37.4546

Grignani, 2012, A phase ii trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An. italian sarcoma group study, Ann. Oncol., 23, 508, 10.1093/annonc/mdr151

Zhang, 1991, Human osteoblasts synthesize and respond to platelet-derived growth factor, Am. J. Physiol., 261, C348, 10.1152/ajpcell.1991.261.2.C348

Sulzbacher, 2000, Platelet-derived growth factor-aa and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma, Mod. Pathol., 13, 632, 10.1038/modpathol.3880109

Kubo, 2008, Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma, Cancer, 112, 2119, 10.1002/cncr.23437

Sulzbacher, 2010, Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome, Pathology, 42, 664, 10.3109/00313025.2010.520310

McGary, 2002, Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor sti571, Clin. Cancer Res., 8, 3584

Bond, 2008, A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children’s oncology group study, Pediatr. Blood Cancer, 50, 254, 10.1002/pbc.21132

Wu, 2012, Methylene diphosphonate-conjugated adriamycin liposomes: Preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo, Biomed. Microdevices, 14, 497, 10.1007/s10544-011-9626-3

Alberts, 2004, Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials, Semin. Oncol., 31, 53, 10.1053/j.seminoncol.2004.08.010

Gorlick, 2009, Novel therapeutic agents for osteosarcoma, Expert Rev. Anticancer Ther., 9, 511, 10.1586/era.09.7

Ory, 2005, Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, 104, 2522, 10.1002/cncr.21530

Lamoureux, 2007, Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies, Expert Rev. Anticancer Ther., 7, 169, 10.1586/14737140.7.2.169

Heymann, 2004, Bisphosphonates: New therapeutic agents for the treatment of bone tumors, Trends Mol. Med., 10, 337, 10.1016/j.molmed.2004.05.007

Cheng, 2004, Alendronate regulates cell invasion and mmp-2 secretion in human osteosarcoma cell lines, Pediatr. Blood Cancer, 42, 410, 10.1002/pbc.20019

Dass, 2007, Zoledronic acid inhibits osteosarcoma growth in an orthotopic model, Mol. Cancer Ther., 6, 3263, 10.1158/1535-7163.MCT-07-0546

Moriceau, 2010, Zoledronic acid potentiates mtor inhibition and abolishes the resistance of osteosarcoma cells to rad001 (everolimus): Pivotal role of the prenylation process, Cancer Res., 70, 10329, 10.1158/0008-5472.CAN-10-0578

Labrinidis, 2009, Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model, Clin. Cancer Res., 15, 3451, 10.1158/1078-0432.CCR-08-1616

Labrinidis, 2010, Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model, Int. J. Cancer, 127, 345, 10.1002/ijc.25051

Theoleyre, 2004, The molecular triad opg/rank/rankl: Involvement in the orchestration of pathophysiological bone remodeling, Cytokine Growth Factor Rev., 15, 457, 10.1016/j.cytogfr.2004.06.004

Grimaud, 2003, Receptor activator of nuclear factor kappab ligand (rankl)/osteoprotegerin (opg) ratio is increased in severe osteolysis, Am. J. Pathol., 163, 2021, 10.1016/S0002-9440(10)63560-2

Mori, 2007, Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, J. Pathol., 211, 555, 10.1002/path.2140

Lee, 2011, Rankl expression is related to treatment outcome of patients with localized, high-grade osteosarcoma, Pediatr. Blood Cancer, 56, 738, 10.1002/pbc.22720

Lamoureux, 2007, Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Res., 67, 7308, 10.1158/0008-5472.CAN-06-4130

Beristain, 2012, Homotypic rank signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells, J. Cell. Sci., 125, 943, 10.1242/jcs.094029

Anderson, 2008, Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (ewing’s sarcoma and osteosarcoma), Expert Opin. Investig. Drugs, 17, 1703, 10.1517/13543784.17.11.1703

Uckum, F.M. (2013). Monoclonal Antibodies in Oncology, eBook Future Medicine Ltd.. Chapter 5.

Heymann, 2012, Anti-rankl therapy for bone tumours: Basic, pre-clinical and clinical evidences, J. Bone Oncol., 1, 2, 10.1016/j.jbo.2012.03.001

Branstetter, 2012, Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone, Clin. Cancer Res., 18, 4415, 10.1158/1078-0432.CCR-12-0578

Ando, 2012, Molecular alterations associated with osteosarcoma development, Sarcoma, 2012, 523432, 10.1155/2012/523432